gatifloxacin has been researched along with fluconazole in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (12.50) | 29.6817 |
| 2010's | 13 (81.25) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Guo, M; Li, C; Li, YR; Liu, JC; Piao, HR; Sun, LP; Zhang, TY; Zheng, CJ | 1 |
| Chi, KQ; Liu, HY; Piao, HR; Sun, LP; Wei, ZY; Yu, ZK; Zheng, CJ | 1 |
| Jin, XJ; Li, MY; Piao, HR; Sun, LP; Yu, ZK; Zhang, TY; Zheng, CJ | 1 |
| Piao, HR; Sun, LP; Wu, J; Zhang, TY; Zheng, CJ | 1 |
| Du, H; Li, J; Liu, H; Piao, H; Sun, D; Sun, L; Zheng, C | 1 |
| Ba, Y; Hou, X; Wang, S; Xu, Z; Yang, H; Zhang, J | 1 |
| Basu, D; Datta, S; Kundu, B; Sa, B; Soundrapandian, C | 1 |
| Basu, D; Datta, S; Sa, B; Soundrapandian, C | 1 |
| Jin, CH; Li, WX; Meng, YQ; Qi, JD; Quan, J; Sun, J; Zhai, HX; Zhang, C | 1 |
1 review(s) available for gatifloxacin and fluconazole
| Article | Year |
|---|---|
Nitroimidazole-containing compounds and their antibacterial and antitubercular activities.
Topics: Anti-Bacterial Agents; Bacterial Infections; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Molecular Structure; Nitroimidazoles | 2019 |
15 other study(ies) available for gatifloxacin and fluconazole
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Synthesis and biological evaluation of 1,3-diaryl pyrazole derivatives as potential antibacterial and anti-inflammatory agents.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antifungal Agents; Candida albicans; Drug Resistance, Multiple, Bacterial; Furans; Gram-Negative Bacteria; Gram-Positive Cocci; Ibuprofen; Indomethacin; Mice; Pyrazoles | 2015 |
Synthesis and biological evaluation of chalcone derivatives containing aminoguanidine or acylhydrazone moieties.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antifungal Agents; Candida albicans; Cell Line; Cell Proliferation; Chalcone; Dose-Response Relationship, Drug; Guanidines; Humans; Hydrazones; Microbial Sensitivity Tests; Molecular Structure; Salmonella typhimurium; Structure-Activity Relationship | 2016 |
Synthesis and evaluation of the antibacterial activities of aryl substituted dihydrotriazine derivatives.
Topics: Anti-Bacterial Agents; Cell Line; Cell Survival; Dose-Response Relationship, Drug; Escherichia coli; Humans; Microbial Sensitivity Tests; Molecular Docking Simulation; Molecular Structure; Pseudomonas aeruginosa; Salmonella typhimurium; Staphylococcus aureus; Structure-Activity Relationship; Triazines | 2018 |
Synthesis of novel dihydrotriazine derivatives bearing 1,3-diaryl pyrazole moieties as potential antibacterial agents.
Topics: Anti-Bacterial Agents; Binding Sites; Cell Line; Cell Survival; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Molecular Docking Simulation; Protein Structure, Tertiary; Pyrazoles; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase; Triazines | 2019 |
Synthesis and biological evaluation of tryptophan-derived rhodanine derivatives as PTP1B inhibitors and anti-bacterial agents.
Topics: Anti-Bacterial Agents; Dose-Response Relationship, Drug; Drug Resistance, Multiple, Bacterial; Enzyme Inhibitors; Microbial Sensitivity Tests; Molecular Structure; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Rhodanine; Structure-Activity Relationship; Tryptophan | 2019 |
Porous bioactive glass scaffolds for local drug delivery in osteomyelitis: development and in vitro characterization.
Topics: Anti-Infective Agents; Biocompatible Materials; Drug Delivery Systems; Fluconazole; Fluoroquinolones; Gatifloxacin; Glass; Humans; Osteomyelitis; Porosity; Solubility | 2010 |
Local drug delivery system for the treatment of osteomyelitis: In vitro evaluation.
Topics: Anti-Infective Agents, Local; Biocompatible Materials; Delayed-Action Preparations; Drug Administration Routes; Drug Carriers; Drug Delivery Systems; Fluconazole; Fluoroquinolones; Gatifloxacin; Glass; Kinetics; Materials Testing; Osteomyelitis; Spectroscopy, Fourier Transform Infrared; Tissue Scaffolds; X-Ray Diffraction | 2011 |
Synthesis and antimicrobial activity evaluation of pyrazole derivatives containing the imidazo[2,1-b][1,3,4]thiadiazole moiety.
Topics: Anti-Bacterial Agents; Antifungal Agents; Fluconazole; Gatifloxacin; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Pyrazoles; Structure-Activity Relationship; Thiadiazoles | 2023 |